NASDAQ:GNOM Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings, & News $46.54 +0.18 (+0.39%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GNOM alerts:Sign Up Key Stats Today's Range$46.54▼$46.8050-Day Range$41.40▼$47.7852-Week Range$30.32▼$51.42Volume3,046 shsAverage Volume8,213 shsMarket Capitalization$52.12 millionAssets Under Management$52.18 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF Overview Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company. Read More Global X Genomics & Biotechnology ETF ExpensesTypeGNOMTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.57%0.57%0.54%0.53%Other Expenses0.00%0.57%0.55%0.52%0.55%Total Expense0.50%0.74%0.76%0.73%0.73%Fee Waiver0.00%-0.74%-0.64%-0.50%-0.62%Net Expense0.50%0.60%0.63%0.62%0.60% Receive GNOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNOM ETF News HeadlinesGlobal X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?May 13, 2026 | americanbankingnews.comGlobal X Genomics & Biotechnology ETF declares semi-annual distribution of $0.0083June 30, 2025 | msn.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 22 at 1:00 AM | Behind the Markets (Ad)10x Genomics Misses Revenue ForecastOctober 29, 2024 | fool.comGlobal X Genomics & Biotechnology UCITS ETF (GNOM.L)August 18, 2024 | finance.yahoo.comGNOM Global X Genomics & Biotechnology ETFJuly 25, 2024 | seekingalpha.comSee More Headlines GNOM ETF - Frequently Asked Questions How have GNOM shares performed this year? Global X Genomics & Biotechnology ETF's stock was trading at $45.46 on January 1st, 2026. Since then, GNOM stock has increased by 2.4% and is now trading at $46.54. When did Global X Genomics & Biotechnology ETF's stock split? Global X Genomics & Biotechnology ETF's stock reverse split on the morning of Tuesday, September 2nd 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Global X Genomics & Biotechnology ETF's major shareholders? Top institutional investors of Global X Genomics & Biotechnology ETF include Bank of America Corp DE (10.70%) and Wealth Management Partners LLC (0.50%). How do I buy shares of Global X Genomics & Biotechnology ETF? Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Global X Genomics & Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Global X Genomics & Biotechnology ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Teladoc Health (TDOC), Intel (INTC), Alibaba Group (BABA) and PayPal (PYPL). Fund Details IssuerGlobal X Fund NameGlobal X Genomics & Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNOM Inception Date4/5/2019 Fund ManagerChang Kim, James Ong, Nam To, Wayne Xie Webwww.completegenomics.com Phone+1-650-9432800Fund Focus Asset ClassEquity BenchmarkSolactive Genomics Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings52 Fund Statistics Assets Under Management$52.18 million Average Daily Volume$0.00 Discount/Premium-0.04% Administrator, Advisor and Custodian AdministratorGlobal X Management Company LLC AdvisorGlobal X Management Company LLC CustodianBrown Brothers Harriman & Co. DistributorSEI Investments Distribution Co. Transfer AgentBrown Brothers Harriman & Co. TrusteeN/A Lead Market MakerSusquehanna Options OptionableOptionable Options Volume1 Put Options1 Call Options1 Short Interest6,100 shs Miscellaneous Outstanding Shares1,120,000Beta1.19 Creation Unit50,000 Creation Fee$500.00 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report Top 10 GNOM HoldingsIllumina (NASDAQ:ILMN)Holding Weight: 4.71%Guardant Health (NASDAQ:GH)Holding Weight: 4.64%Legend Biotech (NASDAQ:LEGN)Holding Weight: 4.52%Arrowhead Pharmaceuticals (NASDAQ:ARWR)Holding Weight: 4.34%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 4.33%Praxis Precision Medicines (NASDAQ:PRAX)Holding Weight: 4.13%Natera (NASDAQ:NTRA)Holding Weight: 4.02%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 3.98%Moderna (NASDAQ:MRNA)Holding Weight: 3.76%CRISPR Therapeutics (NASDAQ:CRSP)Holding Weight: 3.74%Full Holdings DetailsGNOM Sector ExposureGNOM Industry Exposure This page (NASDAQ:GNOM) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersYour computer is about to become a museum pieceVanguard holds $101 billion in three AI companies most investors have never heard of. BlackRock holds $82 bill...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredRevealed: The Best Kept Secrets On Wall StreetTom Busby, founder of the Diversified Trading Institute, is giving away his 'Little Black Book' - a collection...DTI Trader | SponsoredOne algorithm, 17 years, nearly 2,000% total returnsA physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,0...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Global X Genomics & Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
